Novocure Ltd (OQ:NVCR)
Business Focus: Medical Equipment
May 02, 2024 07:01 am ET
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s discretion and subject to certain milestones, through March 31, 2026. The proceeds will be used to fund working capital needs stemmin
Apr 05, 2024 07:00 am ET
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meetin
Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
Apr 01, 2024 07:00 am ET
Novocure to Report First Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months ended March 31, 2024, at 8:00 a.m. EDT on Thursday, May 2, 2024. To access the conference call by phone, use the following
Mar 27, 2024 07:00 am ET
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung C
Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer (NSCLC) following stereotactic radiosurgery (SRS). Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 mo
Mar 11, 2024 07:00 am ET
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3) clinical trial has been selected for presentation at the “Best Oral Session – Late Breaking Abstracts” on Sunday, March 10, 2024 at the European Society on Gynaecological Oncology (ESGO) 2024 Congress in Barcelona.
Feb 22, 2024 07:00 am ET
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
Jan 18, 2024 07:00 am ET
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the U.S. Food and Drug Administration (FDA).
Jan 09, 2024 07:00 am ET
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio® (formerly known as Optune®) concurrent with radiation therapy and temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM).
Jan 08, 2024 07:00 am ET
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
Jan 04, 2024 04:05 pm ET
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncologist and educator. At Novocure, Dr. Leupin will oversee medical affairs, medical safety, and clinical development operations as the company advances its clinical pipeline and prepares to treat an expanded patient population.
Dec 27, 2023 07:00 am ET
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on Wednesday, January 10, 2024. Mr. Doyle and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in one-on-one meetings with investors throughout the event.
Nov 28, 2023 07:30 am ET
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value creation. The plan includes an expected reduction in residual operating expenses of approximately $60 million, enabling the Company to fund future growth priorities without an associated increase in expected forward operating cash burn. Novocure continues to focus resources on its global commercial infrastructure and launch preparation ahead of its anticipated indication in metastatic non-small cell lung cancer and on high-potential
Nov 21, 2023 07:00 am ET
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside chat at 3:30 p.m. EST, as well as one-on-one meetings with investors throughout the event.
Nov 10, 2023 08:00 am ET
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting from Nov. 16 to Nov. 19 in Vancouver, Canada.
Oct 26, 2023 07:00 am ET
Novocure Reports Third Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
Oct 15, 2023 06:05 pm ET
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis of patient-reported health-related global and functional quality of life scores from the
Oct 12, 2023 08:00 am ET
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
Oct 02, 2023 07:00 am ET
Novocure to Report Third Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and nine months ended September 30, 2023, at 8 a.m. EDT on Thursday, October 26, 2023. To access the conference call by phone, use the following
Sep 29, 2023 05:00 pm ET
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTFields) therapy, including new insights about methods to optimize TTFields intensities delivered at the target tumor during treatment.
Sep 08, 2023 04:01 pm ET
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor Treating Fields (TTFields) therapy in the treatment of lung cancer, including a new post-hoc analysis of data from its LUNAR trial in metastatic non-small cell lung cancer.
Sep 02, 2023 07:00 pm ET
Lifshitz Law PLLC Announces Investigations of Peloton Interactive, Inc. (NASDAQ: PTON), DZS Inc. (NASDAQ: DZSI), TriplePoint Venture Growth BDC Corp. (NYSE: TPVG), and NovoCure Ltd. (NASDAQ: NVCR)
Peloton Interactive, Inc. (NASDAQ: PTON) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading...
Aug 30, 2023 05:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of the securities laws.
Aug 29, 2023 06:31 pm ET
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy have been published in The Lancet Oncology.
Aug 28, 2023 07:00 am ET
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at the final analysis. Patients randomized to receive TTFields therapy plus paclitaxel (n=280) demonstrated a median OS of 12.2 months versus a median OS of 11.9 months in patients treated with paclitaxel alone (n=278) (HR: 1.008). Consistent with previously reported studies, TTFields therapy was well-tolerated with no a
Aug 25, 2023 07:00 am ET
Novocure to Participate in Upcoming Investor Conferences
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in the 2023 Wells Fargo Healthcare Conference on September 7, 2023. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 12:45 p.m. ET, as well as one-on-one meetings with investors throughout the event.
Aug 18, 2023 12:22 pm ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NovoCure investors who were...
Aug 18, 2023 11:30 am ET
NVCR LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving NovoCure Limited
NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased NovoCure Limited ("NovoCure") (NASDAQ:NVCR) between January 5, 2023 and June 5, 2023.
Aug 18, 2023 05:00 am ET
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 17, 2023 04:30 pm ET
NVCR LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving NovoCure Limited
NEW YORK, NY / ACCESSWIRE / August 17, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased NovoCure Limited ("NovoCure") (NASDAQ:NVCR) between January 5, 2023 and June 5, 2023.
Aug 17, 2023 12:53 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
The Law Offices of Frank R. Cruz reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ:
Aug 17, 2023 10:15 am ET
NVCR LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving NovoCure Limited
NEW YORK, NY / ACCESSWIRE / August 17, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased NovoCure Limited ("NovoCure") (NASDAQ:NVCR) between January 5, 2023 and June 5, 2023.
Aug 17, 2023 05:00 am ET
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 16, 2023 09:00 pm ET
NOVOCURE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against NovoCure Limited and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against NovoCure Limited (“NovoCure” or the “Company”) (NASDAQQ: NVCR) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired NovoCure securities between January 5, 2023 and June 5, 2023, both dates inclusive (the “Class Period”). Investors have until August 18, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Aug 16, 2023 02:15 pm ET
NVCR LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving NovoCure Limited
NEW YORK, NY / ACCESSWIRE / August 16, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased NovoCure Limited ("NovoCure") (NASDAQ:NVCR) between January 5, 2023 and June 5, 2023.
Aug 16, 2023 01:05 pm ET
DEADLINE ALERT for NVCR, TIGR, GDS, AROW, IBRX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 16, 2023 11:50 am ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws. Class Period: January 5, 2023 to June 5, 2023Lead...
Aug 16, 2023 09:40 am ET
FRIDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that NovoCure Limited Investors with Substantial Losses Have Opportunity to Lead Case – NVCR
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NovoCure Limited (NASDAQ: NVCR) securities between January 5, 2023 and June 5, 2023, all dates inclusive (the “Class Period”) have until this Friday August 18, 2023 to seek...
Aug 15, 2023 07:17 pm ET
NOVOCURE 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against NovoCure Li
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company’s securities between January 5, 2023 to June 5, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Aug 15, 2023 12:15 pm ET
Aug 15, 2023 11:54 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind NovoCure Investors of a Lead Plaintiff Deadline of August 18, 2023
Attention NovoCure Limited ("NovoCure") (NASDAQ: NVCR) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 5, 2023 and June 5, 2023. If you suffered...
Aug 15, 2023 11:05 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired NovoCure Limited (“NovoCure” or the...
Aug 14, 2023 12:49 pm ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NovoCure investors who were...
Aug 14, 2023 10:00 am ET
Calling all investors in NovoCure Limited (NVCR): New lawsuit lead plaintiff deadline is August 18, 2023 - contact Bronstein, Gewirtz & Grossman, LLC today
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) and certain of its...
Aug 14, 2023 09:26 am ET
DEADLINE ALERT for DZSI, and NVCR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 14, 2023 01:45 am ET
NVCR DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NovoCure Limited
Bernstein Liebhard LLP: Do you, or did you, own shares of NovoCure Limited (NASDAQ: NVCR)?Did you purchase your shares between January 5, 2023 and June 5, 2023, inclusive? Did you lose money in your investment in NovoCure Limited?Do you want to...
Aug 13, 2023 11:45 pm ET
Aug 11, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DZS, TriplePoint, NovoCure, and UP Fintech and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DZS, Inc. (NASDAQ: DZSI), TriplePoint Venture Growth BDS Corp. (NYSE: TPVG),...
Aug 11, 2023 12:34 pm ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws. Class Period: January 5, 2023 to June 5, 2023Lead...
Aug 11, 2023 03:00 am ET
7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 10, 2023 01:20 pm ET
NVCR DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages NovoCure Limited Investors with Losses to Secure Counsel Before Important August 18 Deadline in Securities Class Action – NVCR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the “Class Period”), of the important August 18, 2023 lead...
Aug 10, 2023 11:39 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 – (NASDAQ: NVCR)
The Gross Law Firm issues the following notice to shareholders of NovoCure Limited. Shareholders who purchased shares of NVCR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
Aug 10, 2023 09:00 am ET
DEADLINE ALERT for FUTU, DZSI, NVCR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 09, 2023 01:18 pm ET
NVCR SHAREHOLDER ALERT: Jakubowitz Law Reminds NovoCure Shareholders of a Lead Plaintiff Deadline of August 18, 2023
Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR). To receive updates on the lawsuit, fill out the...
Aug 08, 2023 11:45 pm ET
Aug 08, 2023 10:54 pm ET
NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against N
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against...
Aug 08, 2023 07:41 pm ET
NovoCure Limited: Please contact the Portnoy Law Firm to recover your losses; August 18 2023 deadline
The Portnoy Law Firm advises NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) investors that a lawsuit filed on behalf of investors that purchased NovoCure securities between January 5, 2023 to June 5, inclusive (the “Class Period”)...
Aug 08, 2023 01:55 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired NovoCure Limited (“NovoCure” or the...
Aug 08, 2023 01:07 pm ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NovoCure investors who were...
Aug 08, 2023 11:17 am ET
DEADLINE ALERT for FUTU, DZSI, and NVCR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 08, 2023 06:00 am ET
FINAL DEADLINE THIS MONTH: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 08, 2023 01:45 am ET
NOVOCURE LIMITED (NASDAQ: NVCR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NovoCure Limited
Bernstein Liebhard LLP: Do you, or did you, own shares of NovoCure Limited (NASDAQ: NVCR)?Did you purchase your shares between January 5, 2023 and June 5, 2023, inclusive? Did you lose money in your investment in NovoCure Limited?Do you...
Aug 07, 2023 12:03 pm ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws. Class Period: January 5, 2023 to June 5, 2023Lead...
Aug 07, 2023 10:00 am ET
Calling all investors in NovoCure Limited (NVCR): New lawsuit lead plaintiff deadline is August 18, 2023 - contact Bronstein, Gewirtz & Grossman, LLC today
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) and certain of its...
Aug 07, 2023 02:30 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 06, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Futu, DZS, TriplePoint, and NovoCure and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Futu Holdings Ltd. (NASDAQ: FUTU), DZS, Inc. (NASDAQ: DZSI), TriplePoint Venture...
Aug 06, 2023 10:28 am ET
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ: NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 05, 2023 12:58 pm ET
ROSEN, A LEADING NATIONAL FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important August 18 Deadline in Securities Class Action – NVCR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the “Class Period”), of the important August 18, 2023 lead...
Aug 05, 2023 07:47 am ET
IMPORTANT AUGUST DEADLINE ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ: NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 04, 2023 12:40 pm ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NovoCure investors who were...
Aug 04, 2023 09:34 am ET
DEADLINE ALERT for DOYU, FUTU, DZSI, NVCR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 04, 2023 05:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 03, 2023 12:23 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 – (NASDAQ: NVCR)
The Gross Law Firm issues the following notice to shareholders of NovoCure Limited. Shareholders who purchased shares of NVCR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
Aug 03, 2023 05:00 am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 02, 2023 10:52 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of NovoCure Limited - NVCR
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company’s securities between January 5, 2023 to June 5, 2023, inclusive (the “Class Period”)....
Aug 02, 2023 03:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Aug 02, 2023 02:50 pm ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws. Class Period: January 5, 2023 to June 5, 2023Lead...
Aug 02, 2023 11:31 am ET
DEADLINE ALERT for FUTU, DZSI, and NVCR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 02, 2023 06:00 am ET
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 02, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 - (NASDAQ: NVCR)
NEW YORK, Aug. 2, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of NovoCure Limited.
Aug 01, 2023 10:52 pm ET
NOVOCURE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the...
Aug 01, 2023 12:42 pm ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind NovoCure Investors of a Lead Plaintiff Deadline of August 18, 2023
Attention NovoCure Limited ("NovoCure") (NASDAQ: NVCR) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 5, 2023 and June 5, 2023. If you suffered...
Aug 01, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired NovoCure Limited (“NovoCure” or the...
Aug 01, 2023 06:00 am ET
IMPORTANT AUGUST DEADLINE ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 01, 2023 05:45 am ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws.
Aug 01, 2023 01:45 am ET
NVDR DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NovoCure Limited
Bernstein Liebhard LLP: Do you, or did you, own shares of NovoCure Limited (NASDAQ: NVCR)?Did you purchase your shares between January 5, 2023 and June 5, 2023, inclusive?Did you lose money in your investment in NovoCure Limited?Do you want to...
Jul 31, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Futu, DZS, TriplePoint, and NovoCure and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Futu Holdings Ltd. (NASDAQ: FUTU), DZS, Inc. (NASDAQ: DZSI), TriplePoint Venture...
Jul 31, 2023 08:25 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVCR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the “Class Period”), of the important August 18, 2023 lead...
Jul 31, 2023 12:50 pm ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NovoCure investors who were...
Jul 31, 2023 10:00 am ET
Calling all investors in NovoCure Limited (NVCR): New lawsuit lead plaintiff deadline is August 18, 2023 - contact Bronstein, Gewirtz & Grossman, LLC today
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) and certain of its...
Jul 31, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 31, 2023 05:43 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind NovoCure Investors of a Lead Plaintiff Deadline of August 18, 2023
NEW YORK, July 31, 2023 /PRNewswire/ -- Attention NovoCure Limited ("NovoCure") (NASDAQ: NVCR) shareholders:
Jul 29, 2023 07:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ: NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 28, 2023 10:50 pm ET
NOVOCURE SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR
NEW ORLEANS, July 28, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company's securities between January 5, 2023 to June 5, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
Jul 28, 2023 12:30 pm ET
NVCR Investors Have Opportunity to Lead NovoCure Limited Securities Fraud Lawsuit
LOS ANGELES, July 28, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR).
Jul 28, 2023 12:24 pm ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws. Class Period: January 5, 2023 to June 5, 2023Lead...
Jul 28, 2023 06:00 am ET
INVESTOR DEADLINE ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 28, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 28, 2023 05:45 am ET
NVCR SHAREHOLDER ALERT: Jakubowitz Law Reminds NovoCure Shareholders of a Lead Plaintiff Deadline of August 18, 2023
NEW YORK, July 28, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR).
Jul 27, 2023 09:00 pm ET
Lost Money in NovoCure Limited? Gibbs Law Group Investigates Potential Securities Law Violations
Gibbs Law Group announces that a class action lawsuit has been filed on behalf of NovoCure Limited (NASDAQ: NVCR) investors. On June 6, 2023, NovoCure announced results from its Phase 3 LUNAR clinical trial that some doctors say may have included unreliable data, because not all study participants had been receiving standard of care therapy, according to Evaluate. Gibbs Law Group encourages NovoCure investors to contact us to discuss their legal rights and options.
Jul 27, 2023 02:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 27, 2023 02:05 pm ET
Jul 27, 2023 01:28 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 – (NASDAQ: NVCR)
The Gross Law Firm issues the following notice to shareholders of NovoCure Limited. Shareholders who purchased shares of NVCR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
Jul 27, 2023 12:00 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 27, 2023 10:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired NovoCure Limited (“NovoCure” or the...
Jul 27, 2023 07:00 am ET
Novocure Reports Second Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
Jul 27, 2023 05:45 am ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, July 27, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit.
Jul 27, 2023 12:50 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of NovoCure Limited - NVCR
CEDARHURST, N.Y., July 27, 2023 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company's securities between January 5, 2023 to June 5, 2023, inclusive (the "Class Period"). Shareholders have until August 18, 2023 to file lead plaintiff applications in the securities class action lawsuit.
Jul 26, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Futu, DZS, TriplePoint, and NovoCure and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Futu Holdings Ltd. (NASDAQ: FUTU), DZS, Inc. (NASDAQ: DZSI), TriplePoint Venture...
Jul 26, 2023 12:39 pm ET
NVCR SHAREHOLDER ALERT: Jakubowitz Law Reminds NovoCure Shareholders of a Lead Plaintiff Deadline of August 18, 2023
Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR). To receive updates on the lawsuit, fill out the...
Jul 26, 2023 11:16 am ET
DEADLINE ALERT for FUTU, DZSI, and NVCR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 26, 2023 06:00 am ET
INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 26, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 - (NASDAQ: NVCR)
NEW YORK, July 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of NovoCure Limited.
Jul 25, 2023 11:24 pm ET
NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against N
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against...
Jul 25, 2023 03:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 25, 2023 02:25 pm ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NovoCure investors who were...
Jul 25, 2023 09:35 am ET
DEADLINE ALERT for DOYU, FUTU, DZSI, NVCR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 25, 2023 07:00 am ET
NOVOCURE LIMITED (NASDAQ: NVCR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against No
Bernstein Liebhard LLP: Do you, or did you, own shares of NovoCure Limited (NASDAQ: NVCR)?Did you purchase your shares between January 5, 2023 and June 5, 2023, inclusive?Did you lose money in your investment in NovoCure Limited?Do you want to...
Jul 25, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 25, 2023 05:45 am ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
NEW YORK, July 25, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws.
Jul 24, 2023 05:56 pm ET
NovoCure Limited: Please contact the Portnoy Law Firm to recover your losses; August 18 2023 deadline
The Portnoy Law Firm advises NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) investors that a lawsuit filed on behalf of investors that purchased NovoCure securities between January 5, 2023 to June 5, inclusive (the “Class Period”)...
Jul 24, 2023 12:40 pm ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws. Class Period: January 5, 2023 to June 5, 2023Lead...
Jul 24, 2023 10:00 am ET
Calling all investors in NovoCure Limited (NVCR): New lawsuit lead plaintiff deadline is August 18, 2023 - contact Bronstein, Gewirtz & Grossman, LLC today
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) and certain of its...
Jul 24, 2023 06:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 24, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind NovoCure Investors of a Lead Plaintiff Deadline of August 18, 2023
NEW YORK, July 24, 2023 /PRNewswire/ -- Attention NovoCure Limited ("NovoCure") (NASDAQ: NVCR) shareholders:
Jul 24, 2023 01:45 am ET
NOVOCURE LIMITED (NASDAQ: NVCR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against No
Did you lose money on investments in NovoCure Limited? If so, please visit NovoCure Limited Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Jul 22, 2023 09:30 am ET
ROSEN, NATIONAL TRIAL COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVCR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the “Class Period”), of the important August 18, 2023 lead...
Jul 21, 2023 10:50 pm ET
NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against N
NEW ORLEANS, July 21, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company's securities between January 5, 2023 to June 5, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
Jul 21, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TriplePoint, NovoCure, UP Fintech, and GDS and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of TriplePoint Venture Growth BDC Corp. (NYSE: TPVG), NovoCure Limited (NASDAQ:...
Jul 21, 2023 12:47 pm ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NovoCure investors who were...
Jul 21, 2023 08:00 am ET
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with nab-paclitaxel and gemcitabine for the treatment of patients with unresectable, locally advanced pancreatic cancer. An independent data monitoring committee (DMC) reviewed the safety and efficacy data for all patients in the fully enrolled clinical trial. The interim analysis resulted in a DMC recommendation that the clinical trial proceed to final analysis.
Jul 21, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 21, 2023 05:45 am ET
NVCR SHAREHOLDER ALERT: Jakubowitz Law Reminds NovoCure Shareholders of a Lead Plaintiff Deadline of August 18, 2023
NEW YORK, July 21, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR).
Jul 20, 2023 03:06 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 – (NASDAQ: NVCR)
The Gross Law Firm issues the following notice to shareholders of NovoCure Limited. Shareholders who purchased shares of NVCR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
Jul 20, 2023 09:05 am ET
NVCR Investors Have Opportunity to Lead NovoCure Limited Securities Fraud Lawsuit
BENSALEM, Pa., July 20, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR).
Jul 20, 2023 07:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 20, 2023 05:45 am ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, July 20, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit.
Jul 19, 2023 10:33 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of NovoCure Limited - NVCR
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company’s securities between January 5, 2023 to June 5, 2023, inclusive (the “Class Period”)....
Jul 19, 2023 01:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 19, 2023 12:05 pm ET
DEADLINE ALERT for FUTU, DZSI, and NVCR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 19, 2023 11:06 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired NovoCure Limited (“NovoCure” or the...
Jul 19, 2023 06:00 am ET
INVESTOR DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 19, 2023 05:45 am ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws. Class Period: January 5, 2023 to June 5, 2023Lead...
Jul 19, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 - (NASDAQ: NVCR)
NEW YORK, July 19, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of NovoCure Limited.
Jul 18, 2023 10:50 pm ET
NOVOCURE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the...
Jul 18, 2023 02:40 pm ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR
NEW YORK, July 18, 2023 /PRNewswire/ --
Jul 18, 2023 01:10 pm ET
DEADLINE ALERT for DOYU, FUTU, DZSI, NVCR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 18, 2023 10:30 am ET
NOVOCURE LIMITED (NASDAQ: NVCR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against No
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jul 18, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 18, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind NovoCure Investors of a Lead Plaintiff Deadline of August 18, 2023
Attention NovoCure Limited ("NovoCure") (NASDAQ: NVCR) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 5, 2023 and June 5, 2023. If you suffered...
Jul 18, 2023 05:45 am ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
NEW YORK, July 18, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws.
Jul 17, 2023 06:55 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVCR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the “Class Period”), of the important August 18, 2023 lead...
Jul 17, 2023 03:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 17, 2023 10:00 am ET
Calling all investors in NovoCure Limited (NVCR): New lawsuit lead plaintiff deadline is August 18, 2023 - contact Bronstein, Gewirtz & Grossman, LLC today
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) and certain of its...
Jul 17, 2023 06:00 am ET
Jul 17, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind NovoCure Investors of a Lead Plaintiff Deadline of August 18, 2023
NEW YORK, July 17, 2023 /PRNewswire/ -- Attention NovoCure Limited ("NovoCure") (NASDAQ: NVCR) shareholders:
Jul 17, 2023 05:45 am ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NovoCure investors who were...
Jul 16, 2023 09:22 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TriplePoint, NovoCure, UP Fintech, and GDS and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of TriplePoint Venture Growth BDC Corp. (NYSE: TPVG), NovoCure Limited (NASDAQ:...
Jul 14, 2023 10:50 pm ET
NOVOCURE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR
NEW ORLEANS, July 14, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company's securities between January 5, 2023 to June 5, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
Jul 14, 2023 08:16 pm ET
NVCR Investors Have Opportunity to Lead NovoCure Limited Securities Fraud Lawsuit
LOS ANGELES, July 14, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR).
Jul 14, 2023 05:05 pm ET
MOORE KUEHN ANNOUNCES ENCOURAGES NOVOCURE LIMITED INVESTORS TO CONTACT LAW FIRM
NEW YORK, July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against:
Jul 14, 2023 07:00 am ET
Jul 14, 2023 05:45 am ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
NEW YORK, July 14, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws.
Jul 14, 2023 05:45 am ET
NVCR SHAREHOLDER ALERT: Jakubowitz Law Reminds NovoCure Shareholders of a Lead Plaintiff Deadline of August 18, 2023
NEW YORK, July 14, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR).
Jul 13, 2023 11:16 am ET
DEADLINE ALERT for FUTU, DZSI, and NVCR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 13, 2023 07:00 am ET
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 13, 2023 05:45 am ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, July 13, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit.
Jul 12, 2023 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of NovoCure Limited - NVCR
CEDARHURST, N.Y., July 12, 2023 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company's securities between January 5, 2023 to June 5, 2023, inclusive (the "Class Period"). Shareholders have until August 18, 2023 to file lead plaintiff applications in the securities class action lawsuit.
Jul 12, 2023 02:36 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired NovoCure Limited (“NovoCure” or the...
Jul 12, 2023 12:52 pm ET
NVCR SHAREHOLDER ALERT: Jakubowitz Law Reminds NovoCure Shareholders of a Lead Plaintiff Deadline of August 18, 2023
Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR). To receive updates on the lawsuit, fill out the...
Jul 12, 2023 07:00 am ET
Jul 12, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 - (NASDAQ: NVCR)
NEW YORK, July 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of NovoCure Limited.
Jul 11, 2023 11:12 pm ET
NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against N
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against...
Jul 11, 2023 07:43 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, July 11, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 11, 2023 12:47 pm ET
NVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of NovoCure investors who were...
Jul 11, 2023 07:00 am ET
Jul 11, 2023 05:45 am ET
NVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders
NEW YORK, July 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of NovoCure Limited (NASDAQ: NVCR) alleging that the Company violated federal securities laws.
Jul 11, 2023 01:45 am ET
NOVOCURE LIMITED (NASDAQ: NVCR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against No
Bernstein Liebhard LLP: Do you, or did you, own shares of NovoCure Limited (NASDAQ: NVCR)?Did you purchase your shares between January 5, 2023 and June 5, 2023, inclusive?Did you lose money in your investment in NovoCure Limited?Do you want to...
Jul 10, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TriplePoint, NovoCure, and UP Fintech and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of TriplePoint Venture Growth BDC Corp. (NYSE: TPVG), NovoCure Limited (NASDAQ:...
Jul 10, 2023 04:10 pm ET
NOVOCURE INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies NovoCure Investors of a Class Action Lawsuit and Upcoming Deadline
Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) securities between January 5, 2023 and June 5, 2023, inclusive (the “Class...
Jul 10, 2023 01:26 pm ET
ATLX, S, DZSI, NVCR Class Action Update: Johnson Fistel Alerts Shareholders of Ongoing Legal Proceedings
Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the following companies. Investors are encouraged to review the deadlines listed and submit their...
Jul 10, 2023 12:54 pm ET
DEADLINE ALERT for DOYU, FUTU, DZSI, NVCR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 10, 2023 10:00 am ET
Calling all investors in NovoCure Limited (NVCR): New lawsuit lead plaintiff deadline is August 18, 2023 - contact Bronstein, Gewirtz & Grossman, LLC today
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) and certain of its...
Jul 10, 2023 07:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 09, 2023 02:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 08, 2023 02:45 pm ET
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR
NEW YORK, July 8, 2023 /PRNewswire/ --
Jul 08, 2023 06:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 07, 2023 10:50 pm ET
NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against N
NEW ORLEANS, July 7, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company's securities between January 5, 2023 to June 5, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
Jul 07, 2023 05:06 pm ET
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of NovoCure Limited (NVCR) Investors and Encourages Investors to Contact the Firm Before August 18, 2023
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR)...
Jul 07, 2023 11:16 am ET
DEADLINE ALERT for FUTU, DZSI, and NVCR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 07, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 06, 2023 06:00 am ET
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 05, 2023 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of NovoCure Limited - NVCR
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company’s securities between January 5, 2023 to June 5, 2023, inclusive (the “Class Period”)....
Jul 05, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TriplePoint, NovoCure, UP Fintech, and GDS and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of TriplePoint Venture Growth BDC Corp. (NYSE: TPVG), NovoCure Limited (NASDAQ:...
Jul 05, 2023 12:30 pm ET
SHAREHOLDER CLASS ACTION REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NovoCure Limited (NASDAQ: NVCR)
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Jul 05, 2023 12:15 pm ET
NovoCure Limited (NVCR) Shareholders: Contact Robbins LLP for Information About the Class Action Against NovoCure Limited
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired NovoCure Limited (NASDAQ: NVCR) securities between January 5, 2023 and June 5, 2023. NovoCure Limited...
Jul 05, 2023 11:07 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired NovoCure Limited (“NovoCure” or the...
Jul 05, 2023 01:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NovoCure Limited ("NovoCure" or "the Company") (NASDAQ:NVCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jul 04, 2023 10:28 pm ET
NOVOCURE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the...
Jul 03, 2023 06:32 pm ET
ROSEN, A LEADING NATIONAL FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVCR
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NovoCure Limited (NASDAQ: NVCR) between January 5, 2023 and June 5, 2023, both dates inclusive (the “Class Period”), of the important August 18, 2023 lead...
Jul 03, 2023 05:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, July 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.